Verastem, Inc. (VSTM) Form 8-K Summary
Business Context and Reporting Period
Verastem, Inc., a Delaware corporation, filed this Current Report on Form 8-K on August 6, 2026. The filing serves to report the Company's financial results for the quarter ended June 30, 2026. The Company's common stock trades on The Nasdaq Capital Market under the symbol "VSTM."
Key Financial Metrics
This Form 8-K is a notification of results and does not contain specific financial data points within the text provided. Revenue, profit, cash flow, margins, debt, and liquidity figures are not listed in this document. The filing states that detailed results are contained in a press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the source text.
Material Changes
The filing does not provide specific numerical comparisons to prior periods. It only indicates that the Company has issued a press release regarding its second-quarter 2026 performance.
Guidance, Outlook, and Risks
The text of this 8-K does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies. These items are presumed to be detailed in the referenced press release (Exhibit 99.1).
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2026 revenue, net loss, and cash position figures.
- Verify the Company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full disclosure.
- Confirm if the Company provided updated full-year 2026 financial guidance in the press release.